TY - JOUR ID - 88762 TI - The Significance of Sidedness in Patients with Metastatic Colorectal Cancer Treated with Triplet First-line Chemotherapy JO - Asian Pacific Journal of Cancer Prevention JA - APJCP LA - en SN - 1513-7368 AU - Bazarbashi, Shouki AU - Omar, Ayman T AU - Raddaoui, Leen AU - Badran, Ahmed AU - Alzahrani, Ahmed AU - Aljubran, Ali AU - Elhassan, Tusneem AD - Section of Medical Oncology, Department of Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. AD - College of Medicine, Alfaisal University, Riyadh, Saudi Arabia. AD - Research Unit, Department of Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. Y1 - 2019 PY - 2019 VL - 20 IS - 10 SP - 2891 EP - 2896 KW - colorectal cancer KW - sidedness KW - Chemotherapy DO - 10.31557/APJCP.2019.20.10.2891 N2 - Background: Recent data have shown that right-sided colon cancer carries poorer prognosis compared to left-sided tumors. This study was aimed to evaluate the progression-free survival, overall survival of patients with metastatic colon cancer of right-sided versus left-sided primaries treated with triplet chemotherapy regimen. Methods: The medical records of patients with metastatic colorectal cancer treated on phase I-II trial of combination Irinotecan, oxaliplatin, capecitabine, and bevacizumab were reviewed for sidedness of the primary. The analysis was performed for progression-free survival and overall survival according to the sidedness and other known prognostic factors. Results: Out of 53 patients treated with triplet therapy, 11 had right sided and 42 had left-sided primaries. The median age for right-sided primaries was 46 (range 24-55) compared to 53 (range 32-74) in left-sided primaries. Median progression-free survival was 14 months for right vs 18 months for left sided tumors (Hazard ratio 0.72, 95% confidence interval 0.27-1.88, p=0.492) and median overall survival was 21 months for right vs 29 months for left sided tumors (Hazard ratio was 0.86, 95% CI 0.32-2.26, p=0.752). Conclusion: First-line triplet chemotherapy may overcome the difference in prognosis between right sided and left sided primaries in metastatic colorectal cancer. A larger analysis is warranted. UR - https://journal.waocp.org/article_88762.html L1 - https://journal.waocp.org/article_88762_d761ff9bf1a460b1cc9271bbac6f6784.pdf ER -